Why Veradermics, Incorporated’s (MANE) Stock Is Down 6.30%
As of Wednesday, September 09, Veradermics, Incorporated’s MANE share price has dipped by 6.30%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Commentary & Analysis
Why Veradermics, Incorporated’s (MANE) Stock Is Down 7.12%
As of Monday, August 24, Veradermics, Incorporated’s MANE share price has dipped by 7.12%, which has investors questioning if this is right time to buy.Michael Rose
Why Veradermics, Incorporated’s (MANE) Stock Is Up 5.61%
As of Friday, August 21, Veradermics, Incorporated’s MANE share price has surged by 5.61%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Veradermics, Incorporated’s (MANE) Stock Is Down 5.11%
As of Monday, August 17, Veradermics, Incorporated’s MANE share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Veradermics, Incorporated’s (MANE) Stock Is Down 5.66%
As of Monday, August 10, Veradermics, Incorporated’s MANE share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MANE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,135.0 | $609.5 | 64% |
|
| Shares Out (Mil) | 40.4 | 43.4 | 43% |
|
| Institutional Ownership | 96.6% | 83.9% | 70% |
|
| Float (Mil) | 32.3 | 45.7 | 38% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 524 | 309 | 60% |
|
| Price Change (52-week) |
na | 64.9% | na |
|
| Growth | MANE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.591) | ($2.939) | ($2.687) | |
| Month Ago EPS | ($0.616) | ($2.858) | ($2.839) | |
| # Rev Up | 2 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.646) | ($3.050) | ($3.038) | |
| Year/Year Chg | 1.7% | (97.4%) | (98.9%) | |
| Financials | MANE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($93) | ($11) | 12% |
|
| EPS (TTM) | ($6.444) | ($0.700) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($7) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $290 | $6 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 14% |
|
| Enterprise Value (Q1) (Mil) | $3,818 | $525 | 58% |
|
| Valuation | MANE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.08 | 2.61 | 79% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MANE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | 0.8% | na |
|
| ROA | (22.4%) | (22.7%) | 19% |
|
| ROE | (24.3%) | (22.8%) | 22% |
|
| Liabilities to Assets | 1.5% | 33.1% | 0% |
|
| F-Score | 1 | 3 | na |
|
Veradermics, Incorporated did not pass any screens on 9/11/2026.
